Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer
Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The prognosis of metastatic gastric cancer is poor. Chemotherapy occasionally converts an
initially unresectable gastric cancer to a resectable cancer. Previous studies showed
patients with unresectable gastric cancer may obtain a survival benefit from chemotherapy and
subsequent curative surgery. The key of conversion therapy of initially unresectable
metastatic GC is the high response rate. Apatinib, a novel targeted inhibitor of VEGF
receptor 2 (VEGFR2), shows significant antitumor activity in the patients with GC. The
purpose of this study is to investigate the efficacy and safety of S1/Paclitaxel chemotherapy
plus Apatinib in the conversion therapys of metastatic gastric cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhejiang Chinese Medical University